Advanced NSCLC Clinical Trial
Official title:
Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00813332 -
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
|
Phase 4 | |
Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04982224 -
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05609578 -
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
|
Phase 2 | |
Not yet recruiting |
NCT04992858 -
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
|
Phase 2 | |
Not yet recruiting |
NCT06356675 -
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
|
Phase 4 | |
Completed |
NCT03074175 -
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer:Multicenter Controlled Study.(RadmiR-01)
|
N/A | |
Terminated |
NCT05106335 -
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04229121 -
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
|
||
Completed |
NCT05219162 -
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
|
Phase 4 | |
Not yet recruiting |
NCT05859217 -
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
|
Phase 2 | |
Recruiting |
NCT03062800 -
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
|
Phase 2 | |
Completed |
NCT02055508 -
POSITIVE - Study (Part III) Heidelberg
|
N/A | |
Active, not recruiting |
NCT04043195 -
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
|
Phase 1/Phase 2 |